Articles tagged with Prostate Cancer
Researchers found a biomarker that identifies men with a five-fold increased risk of prostate cancer recurrence if their tumors show silencing of the CDH13 gene. The study, which examined DNA methylation changes in 151 research subjects, suggests a potential tool to improve prediction accuracy and inform clinical practice.
Researchers found a single PSA test can predict advanced prostate cancer with high accuracy, allowing for targeted screening and potentially reducing overdiagnosis. The study revealed that men with higher PSA levels are at increased risk of developing advanced cancer, highlighting the potential for early detection to improve outcomes.
Researchers discovered a correlation between pre-treatment biopsy samples and post-treatment positive biopsies in high-risk prostate cancer patients. This information can help doctors tailor radiation treatment to reduce recurrence rates.
A new study finds that eating a diet low in fat and red meat, but high in vegetables and lean protein, may significantly decrease the risk of symptomatic benign prostatic hyperplasia (BPH). This association is likely due to reduced inflammation and changes in steroid hormones.
Researchers found that men with physically active jobs had a lower risk of developing prostate cancer compared to those with low-activity jobs. The study also revealed that increased physical activity was associated with reduced exposure to carcinogenic chemicals.
Researchers at Henry Ford Hospital are conducting a phase III clinical trial to determine the effectiveness of gene therapy in combination with radiation therapy for patients with intermediate risk prostate cancer. The trial aims to improve patient outcomes by delaying hormone therapy, which can have severe side effects.
Localized prostate cancer treatment options face uncertainty due to limited evidence. Gene expression tests for breast cancer hold promise but require further data on benefits and limitations. New HIV treatment guidelines suggest earlier initiation may increase life expectancy for younger patients. Pregnant women should not be screened...
A new urine test detects prostate cancer more accurately than current methods, including PSA and PCA3 tests. The test identified 80% of patients with prostate cancer and was 61% effective in ruling out disease.
Researchers have developed a successful test vaccine that prevents the development of prostate cancer in 90% of young mice. The vaccine targets prostate stem cell antigen (PSCA), which is over-expressed in early-stage prostate cancers, and has been shown to mount an immune response against the protein.
A recent study published in The Prostate found that men with low zinc levels and high cadmium exposure had a 22% higher PSA level, indicating a higher risk of prostate cancer. Conversely, those with high zinc intake showed little evidence of an association between cadmium and PSA levels.
Men with prostate cancer who undergo radical prostatectomy experience significant urinary and sexual dysfunction, including incontinence and depression. Health-care practitioners must educate patients about these side effects to improve quality of life.
A new model predicts prostate cancer progression based on Gleason score and biomarker assessments, providing valuable information for patient management and treatment planning. The research has potential benefits for patients diagnosed with early prostate cancer.
A collaborative analysis of 18 prospective studies found no link between circulating sex hormones and prostate cancer risk. High levels of male sex hormones were previously thought to be a risk factor, but the results indicate that testosterone and estrogen do not play a significant role in prostate cancer development.
A multidisciplinary team led by Dr. Neil Bander will develop a novel nanomedicine for prostate cancer, targeting specific sites with high PSMA presence. The collaboration aims to create synergies in research and development, potentially reducing side effects and increasing effectiveness.
A molecular change found in human prostate cancers triggers growth of prostate cancer in mice and human cell lines. The overexpression of ERG transcription factor is thought to activate cell-invasion programs, displacing basal cells by neoplastic epithelium.
The American College of Preventive Medicine (ACPM) advises that clinicians provide information on potential benefits and harms of prostate cancer screening to men, especially those with family history or African-American background. Patient-clinician discussion is crucial for informed decision-making about screening.
Men with localized prostate cancer who received male hormone suppression therapy and radiation treatment had longer survival rates. However, those with moderate to high levels of comorbid illnesses did not experience this effect. Combination therapy improved overall survival in men without severe comorbidity.
Researchers analyzed data from the National Cancer Institute's Prostate Cancer Prevention Trial, showing that finasteride reduces prostate cancer risk by 25% but also causes side effects like impotence. The study encourages men to consider both benefits and drawbacks before taking the drug to prevent prostate cancer.
Researchers have identified a new gene test that can identify men with a higher risk of developing prostate cancer. The study found that men carrying a combination of known risk genes are four to five times more likely to develop the disease, providing a potential breakthrough in early detection and treatment.
A new genomics research found that a simple blood test can determine which men are likely to develop prostate cancer. Researchers identified five genetic variants associated with prostate cancer risk, which combined could account for 40% of cases.
A panel of genetic markers, derived from a study of Swedish men, has been identified as common causes of hereditary prostate cancer. These markers, combined with family history, increase the risk of the disease by nearly nine times, accounting for nearly half of all cases in this population.
A new study from Danish researchers has found that childless men have a lower risk of developing prostate cancer than fathers, with a reduced risk associated with having more children. The study suggests that this may be due to a "healthy father" phenomenon, where fertile men are less likely to develop the disease.
Researchers at Thomas Jefferson University have found that nearly all recurrent prostate cancers resistant to hormone therapy activate a signaling protein called Stat5, making it a potential drug target. The convergence of two biological pathways may also contribute to the development of aggressive hormone-resistant tumors.
Researchers identified a genetic variant of the DAB2IP gene associated with an increased risk of advanced prostate cancer. The finding may lead to better risk assessment and personalized treatment options for men diagnosed with prostate cancer.
Researchers identified a variant of the tumor suppressor gene DAB2IP associated with aggressive prostate cancer. A study of nearly 1,000 Swedish men and two independent groups confirmed the link, suggesting this gene plays a role in prostate cancer progression.
Researchers at Baylor College of Medicine developed a mouse model to study prostate cancer progression, revealing the role of fibroblast growth factor receptor 1 in initiating cancer. The study identified key genes involved in cell plasticity and discovered a new marker for human prostate cancer.
Researchers identified two proteins, hnRNP-H1 and SAFB-2, as potential biomarkers for disease screening in African-American men. These proteins are involved in the growth of tumor cells and may play a role in hormone-related prostate cancer progression.
African-American men face an observable disadvantage in prostate cancer survival due to genetic and behavioral differences. Research highlights the impact of cultural beliefs, such as fatalism and religiosity, on cancer detection and control, as well as the link between obesity and advanced-stage prostate cancer diagnosis.
Researchers at UC Davis identified a cellular pathway involving microRNA miR-125b that contributes to the progression of prostate cancer. The discovery provides a potential target for reducing cancer deaths among American men.
A study found that many prostate cancer patients receive treatment contraindicated by pre-existing conditions, such as urinary or bowel dysfunction. This 'mismatched' therapy can lead to worsened symptoms and outcomes.
A study found that over 89% of men with early prostate cancer received inappropriate therapies due to pre-existing problems. The mismatched treatments may be attributed to patients' reluctance to discuss symptoms with their physicians.
A new study led by Duke Prostate Center researchers found that obese men may be missing cancers because the blood marker used to detect prostate cancer can be diluted in their bodies. The concentration of prostate-specific antigen (PSA) in the blood is lower in obese men due to increased blood volume.
Research found that higher body mass index (BMI) is associated with greater plasma volume, leading to lower PSA concentrations among obese men. The study of over 13,000 men with prostate cancer suggests a possible explanation for the observed association between obesity and decreased PSA levels.
The S.T.A.R. Program brings together researchers from top cancer centers to explore the role of targeted heat in cancer therapy for prostate cancer. The program aims to selectively heat cancer cells while preventing damage to adjacent healthy tissues.
A structured support program improved prostate cancer patients' and their spouses' lives by addressing symptom management, hope, and couples' communication. The intervention also reduced mental health distress and increased physical quality of life.
A new study from the University of Michigan Comprehensive Cancer Center shows that targeted interventions for caregivers can significantly improve their physical and emotional quality of life. The FOCUS Program, a family-based intervention, provided benefits for spouses of prostate cancer patients, including reduced uncertainty and imp...
Men diagnosed with prostate cancer who are overweight or obese have a higher risk of death after treatment, according to a new study. The study found that being overweight or obese at diagnosis was an independent risk factor for prostate cancer-specific mortality.
A genetic variant on chromosome 8q24 is associated with a higher risk of prostate cancer in African Americans. The study found that common genetic variants are linked to elevated prostate cancer risk, particularly among this high-risk population.
A study of over 11,000 men found that those receiving radiation seed implants had a significant reduction in mortality risk compared to those on watchful waiting/active surveillance within six months of diagnosis. Brachytherapy was shown to be as effective as radical prostatectomy and surgery in extending life expectancy.
Researchers have discovered a new genetic variant, rs7008482, strongly associated with increased prostate cancer risk in African-American men. This variation is located within a gene involved in DNA repair and may confer an inherited predisposition to genetic instability.
A large-scale analysis of over 2,000 patients reveals that men with high-risk prostate cancer who receive radiation therapy after a prostatectomy are less likely to experience disease recurrence. Additionally, men whose cancer persists after surgery benefit from reduced cancer spread if they receive salvage therapy.
Men with low-risk prostate cancer who miss two or more radiation treatments in an eight-week course face a higher chance of their cancer recurring. The study of nearly 1,800 patients found that controlling cancer within the prostate and preventing its spread outside makes the greatest difference for these patients.
A large retrospective study found that radiation seed implants (brachytherapy) are equally effective in curing localized prostate cancer in men aged 60 and younger. The study results suggest that younger men should be presented with all viable treatment options, including brachytherapy, regardless of age.
A new study by Fox Chase Cancer Center found that higher doses of radiation therapy for prostate cancer do not lead to decreased sexual function. The research used intensity-modulated radiation therapy (IMRT) and showed no significant difference in sexual function scores between two treatment groups.
Researchers at Oregon Health & Science University have found that highly targeted radiation therapy can prevent long-term rectal damage in prostate cancer patients. The combination of intensity-modulated radiation and seed marker-based image-guided radiation therapies resulted in nearly 98% of participants having no rectal damage.
Prostate cancer patients undergoing hormone therapy who walked five times a week maintained or gained bone density, while those who didn't exercise lost more than two percent of their bone density. A nurse-directed home-based walking program improved physical function and managed symptoms during radiation and hormone treatment.
Researchers share comprehensive lifestyle advice to avoid prostate cancer, including eating tomatoes and fish, maintaining a healthy weight, and avoiding high-temperature meat cooking. Experts recommend specific dietary modifications to delay or avoid aggressive treatments.
A study of over 60,000 Danish men found that prostate cancer increases the risk of hip fractures by eight times in men aged 50-65. The researchers discovered that prostate cancer made men 1.8 times more likely to suffer a fracture and 3.7 times as likely to suffer from a hip fracture.
Researchers have discovered new small molecules that can prevent prostate cancer cells from turning off normal genes by blocking the action of a methyl-CpG binding protein. This breakthrough has significant implications for the development of targeted therapies for prostate and other cancers.
Researchers detected androgen-synthesizing proteins in prostate cancer cells, which may explain why some cancers become resistant to therapies. This discovery offers new directions for research into future treatments that could block the development of androgens in cancer cells.
Researchers questioned the effectiveness of PSA velocity as a prostate cancer screening tool due to inconsistent study results and potential biases. Despite initial hopes that it could reduce unnecessary biopsies, PSA velocity is often used in men with low PSA levels, increasing the number of referrals.
A study by Duke University researchers found that African-American men have a slightly higher risk of PSA recurrence after prostate cancer treatment. Despite this, the disease's aggressiveness remains similar across racial groups.
People with a history of allergies have a nearly third lower risk of developing certain brain cancers, such as glioma. Meanwhile, genetic studies identified three locations on human chromosome 8q24 associated with an increased risk of prostate cancer.
A study published in Journal of the National Cancer Institute found that androgen deprivation therapy used to treat localized prostate cancer increases the risk of death from heart disease. The therapy can lead to metabolic syndrome, which raises the risk of type II diabetes or coronary artery disease.
A Swiss study suggests that surgery is the most effective treatment option for long-term prostate cancer survival, particularly among younger patients and those with poorly differentiated tumors. The study found higher 10-year survival rates for men who underwent prostatectomy compared to radiotherapy or watchful waiting.
Men with Gleason score 7 and tertiary grade 5 disease have a shorter time to PSA failure than those with Gleason score 8-10. This finding may affect management of care for men with prostate cancer.
A study by Johns Hopkins researchers found that standard androgen deprivation therapy for prostate cancer may increase the production of nestin, a protein that promotes cell migration and metastasis. The therapy is effective in slowing tumor growth but may inadvertently encourage cancer cells to spread throughout the body.
A study of deceased men found that prostate cancer diagnosis depends more on the biopsied area than sample number, suggesting a new approach to design biopsies. Alternative trial designs and targeting tumor microenvironments may also improve cancer treatment outcomes.
The Phase II study found a 45% reduction in risk of death and improved median overall survival of 24.5 months for patients treated with ZD4054 10mg once-daily compared to placebo.
The Phase II EPOC study found that ZD4054, an endothelin A receptor antagonist, showed no difference in progression-free survival but reported encouraging overall survival data. The compound may have potential to increase median overall survival time for men with asymptomatic or mildly symptomatic metastatic HRPC.